Table 2.
Next-generation bispecific antibodies targeting Tregs in tumor immunotherapy.
| Drug name | Target | IgG Type | Cancer type | Company | Year of approved/clinical phase |
|---|---|---|---|---|---|
| Cadonilimab | CTLA4, PD-1 | IgG1 | cervical cancer, | Akeso | 2022 |
| Tebotelimab | LAG3, PD-1 | IgG4 | Breast, endometrial, esophageal, gastric head and neck Cancer | MacroGenics | Phase 2/3 NCT04082364 |
| RG-6139 | LAG3, PD-1 | – | Esophageal, liver, non-small-cell lung cancer, melanoma | Roche | Phase 2 NCT05419388 |
| AZD-7789 | TIM3, PD-1 | – | Advanced solid tumor, hodgkins disease, metastatic non-small-cell lung cancer | AstraZeneca | Phase 1/2 NCT05216835 |
| RG-7769 | TIM3, PD-1 | – | Esophageal, non-small-cell lung Cancer, malignant melanoma | Roche | Phase 2 NCT04785820 |
| AZD-2936 | TIGIT, PD-1 | – | Non-small-cell lung cancer | AstraZeneca | Phase 1/2 NCT04995523 |
| IBI-363 | CD25, PD-1 | – | Advanced solid tumor, lymphoma | Innovent Biologics | Phase 1 NCT04995523 |
| ATOR-1015 | OX40, CTLA4 | IgG1 | Melanoma, metastatic colorectal, cancer, metastatic renal cell carcinoma | Alligator | Phase 1 NCT03782467 |
| ATOR-1144 | GITR, CTLA4 | IgG1 | Solid tumors, hematological malignancies | Alligator | Preclinical |
| INV-322 | CD25, CTLA4 | IgG1 | Solid tumor | Invenra | Preclinical |
"-" indicates that no relevant information was found.